Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185601 | 0.85 | LMNA (0.59) | MAPK8LMNAMAPK1NLRP1EPHX2 | |
| SCHEMBL4199798 | 0.84 | EPHX2 (0.67) | LMNAMAPK1NLRP1EPHX2P2RX7 | |
| SCHEMBL4197581 | 0.81 | EPHX2 (0.76) | MAPK8LMNAMAPK1NLRP1EPHX2 | |
| SCHEMBL4199381 | 0.79 | P2RX7 (0.53) | MAPK8LMNAMAPK1NLRP1EPHX2 | |
| SCHEMBL4189333 | 0.78 | LMNA (0.53) | MAPK8LMNAMAPK1NLRP1EPHX2 | |
| SCHEMBL5645070 | 0.77 | LMNA (0.64) | LMNAMAPK1NLRP1EPHX2TSHR | |
| SCHEMBL4189507 | 0.77 | EPHX2 (0.74) | MAPK8LMNAMAPK1NLRP1EPHX2 | |
| SCHEMBL14456958 | 0.77 | CRHBP (0.42) | MAPK8EPHX2P2RX7 | |
| SCHEMBL5642926 | 0.76 | LMNA (0.75) | LMNAMAPK1NLRP1EPHX2TSHR | |
| SCHEMBL5646507 | 0.76 | LMNA (0.70) | LMNAMAPK1NLRP1EPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| WO-2007098352-A2 | SUBSTITUTED PYRIDINEAMIDE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | MAPK8 2623/4885LMNA 2116/4885MAPK1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.